Oncorus, Inc.
Index- P/E- EPS (ttm)-2.95 Insider Own0.20% Shs Outstand25.97M Perf Week-30.39%
Market Cap12.02M Forward P/E- EPS next Y-1.60 Insider Trans0.00% Shs Float23.66M Perf Month-28.79%
Income-76.30M PEG- EPS next Q-0.65 Inst Own65.30% Short Float / Ratio3.60% / 9.64 Perf Quarter-62.34%
Sales- P/S- EPS this Y2.00% Inst Trans-2.60% Short Interest0.85M Perf Half Y-59.35%
Book/sh3.08 P/B0.15 EPS next Y40.70% ROA-42.10% Target Price5.75 Perf Year-92.09%
Cash/sh3.12 P/C0.15 EPS next 5Y- ROE-72.30% 52W Range0.41 - 6.08 Perf YTD-91.28%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-92.44% Beta-
Dividend %- Quick Ratio5.00 Sales past 5Y- Gross Margin- 52W Low12.05% ATR0.10
Employees82 Current Ratio5.00 Sales Q/Q- Oper. Margin- RSI (14)34.49 Volatility17.09% 17.31%
OptionableYes Debt/Eq0.24 EPS Q/Q-16.30% Profit Margin- Rel Volume0.78 Prev Close0.45
ShortableYes LT Debt/Eq0.24 EarningsNov 02 BMO Payout- Avg Volume88.43K Price0.46
Recom2.00 SMA20-20.31% SMA50-34.54% SMA200-63.90% Volume68,927 Change2.07%
Mar-16-21Initiated Maxim Group Buy $35
Oct-27-20Initiated Piper Sandler Overweight $40
Oct-27-20Initiated Jefferies Buy $22
Oct-27-20Initiated Evercore ISI Outperform $35
Nov-30-22 01:16PM
Nov-23-22 08:00AM
Nov-18-22 08:00AM
12:00PM Loading…
Nov-07-22 12:00PM
Nov-02-22 07:00AM
Oct-07-22 09:00AM
Sep-26-22 07:00AM
Sep-06-22 07:00AM
Aug-16-22 06:22AM
Aug-04-22 07:00AM
Jul-13-22 09:55AM
Jul-06-22 08:05AM
Jun-23-22 07:00AM
02:51PM Loading…
Jun-15-22 02:51PM
Jun-01-22 07:00AM
May-17-22 07:00AM
May-10-22 07:00AM
May-04-22 07:00AM
Apr-08-22 01:00PM
Apr-05-22 07:00AM
Mar-21-22 07:00AM
Mar-10-22 07:00AM
Mar-09-22 07:00AM
Feb-22-22 08:00AM
Jan-03-22 07:00AM
Nov-29-21 06:13AM
Nov-23-21 07:00AM
Nov-17-21 07:00AM
03:11PM Loading…
Nov-12-21 03:11PM
Nov-11-21 07:00AM
Nov-09-21 08:00AM
Nov-08-21 10:50AM
Nov-03-21 07:00AM
Oct-01-21 08:00AM
Sep-29-21 10:58AM
Sep-22-21 10:15AM
Aug-04-21 07:00AM
Jul-29-21 07:00AM
Jul-01-21 05:16AM
Jun-17-21 07:00AM
Jun-15-21 07:57AM
May-27-21 07:05AM
May-26-21 07:00AM
May-04-21 07:00AM
Apr-02-21 05:04AM
Mar-10-21 07:00AM
Feb-12-21 09:31AM
Feb-11-21 10:15PM
Feb-09-21 05:01PM
Jan-20-21 07:00AM
Jan-04-21 07:00AM
Jan-02-21 03:59AM
Dec-14-20 08:00AM
Dec-07-20 08:00AM
Nov-24-20 08:00AM
Nov-12-20 07:00AM
Nov-11-20 07:00AM
Oct-05-20 04:05PM
Oct-02-20 11:23AM
Oct-01-20 07:12PM
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wanstall RickCFO and TreasurerMay 25Buy1.203,7774,53251,000May 25 04:51 PM
Wanstall RickCFO and TreasurerMay 20Buy1.201,6101,93247,223May 24 04:30 PM
Wanstall RickCFO and TreasurerMay 19Buy1.295,0006,45045,613May 19 04:15 PM
Wanstall RickCFO and TreasurerMay 17Buy1.201140,613May 19 04:15 PM